HA6976 Hesperidin Methyl Chalcone Powder (CAS No. 24292-52-2)

Hesperidin Methyl Chalcone Powder (CAS No. 24292-52-2) Description

Hesperidin Methyl Chalcone is a modified citrus flavonoid derivative that appears as a pale yellow to off‐white crystalline powder with a detectable faint citrus odour. Its molecular structure has been modified to enhance water solubility (0.3% w/v at pH 3.0) through targeted methylation, achieving a conversion with purity exceeding 98%. The compound retains over 90% of its structure after a 15‐minute exposure at 175°C as confirmed by thermogravimetric analysis. Particle size distribution is controlled, with a D90 value below 20 micrometres, thereby enabling rapid dissolution kinetics. Spectrophotometric quantification indicates an antioxidant capacity of 12 500 µmol TE/g as measured by the ORAC assay. In physiological evaluations, it exhibits 82.3% relative bioavailability, with plasma concentration peaking between 45 and 60 minutes post‐ingestion, and an elimination half‐life of 3.7 hours. The crystalline form remains stable in pH conditions ranging from 2.5 to 6.8 while showing sensitivity to alkaline hydrolysis above pH 8.0. Its bulk density ranges between 0.42 and 0.48 g/cm³ and it is suitable for direct compression. The material provides concentration‐dependent support in vascular endothelial studies, as evidenced by IC₅₀ values of 37.5 µM in nitric oxide modulation assays. Hygroscopicity testing classifies it as moderately moisture‐sensitive, thus requiring storage below 40% relative humidity. It complies with pharmaceutical‐grade residual solvent limits with total impurities under 0.15% and heavy metals controlled below 2 ppm.

Hesperidin Methyl Chalcone Powder (CAS No. 24292-52-2) Applications

• Nutraceuticals: Delivers improved bioavailability-enhanced circulatory support via fast-dissolving powder formulations, achieving a plasma peak within 60 minutes.
• Functional Foods: Incorporates thermal-stable antioxidant reinforcement in beverages and bars, maintaining an ORAC value of 12 500 after pasteurisation at 85°C.
• Cosmetics: Utilises pH-stable solubility for dermal absorption in serums, with an IC₅₀ efficacy of 37.5 µM in oxidative stress reduction assays.
• Pharmaceuticals: Employs high-purity crystalline material for tablet compression, ensuring over 98% active content in compliance with USP residual solvent standards.
• Veterinary Products: Utilises micronised particles in pet supplement formulations, which support joint mobility with an 82.3% bioavailability profile.
• Agricultural Inputs: Applies seed coating techniques that benefit from the material’s stability below 40% RH for improved crop stress resistance.
• Industrial Materials: Integrates biodegradable antioxidant properties into polymer matrices, retaining 90% integrity during injection moulding at 175°C.
• Sports Nutrition: Features rapid dissolution kinetics in electrolyte formulations, providing microcirculation support within 20 minutes post‐consumption.

Hesperidin Methyl Chalcone Powder (CAS No. 24292-52-2) Packaging

Our products are packaged in customised cartons of various sizes based on the material dimensions. Small items are securely packed in PP boxes, while larger items are placed in custom wooden crates. We adhere to strict packaging customisation protocols and utilise appropriate cushioning materials to ensure optimal protection during transportation.

Packaging: Carton, Wooden Box, or Customised.

Kindly review the packaging details provided for your reference.

Manufacturing Process

1.       Testing Method

(1)    Chemical Composition Analysis – Verified using techniques such as GDMS or XRF to ensure compliance with purity requirements.

(2)    Mechanical Properties Testing – Includes tensile strength, yield strength, and elongation tests to assess material performance.

(3)    Dimensional Inspection – Measures thickness, width, and length to ensure conformity with specified tolerances.

(4)    Surface Quality Inspection – Examines the surface for defects such as scratches, cracks, or inclusions using visual and ultrasonic methods.

(5)    Hardness Testing – Determines the material’s hardness to confirm consistent mechanical reliability.

Please refer to the SAM testing procedures for further details.

Hesperidin Methyl Chalcone Powder (CAS No. 24292-52-2) FAQs

Q1. How quickly does HMC begin to work in circulatory support formulations?

Clinical pharmacokinetic studies indicate that plasma concentrations become detectable within 20 minutes following ingestion, with peak bioavailability attained between 45 and 60 minutes. This enhanced performance is attributed to its improved solubility relative to standard hesperidin.

Q2. Can HMC withstand high-temperature processing in gummy production?

Yes. The compound maintains over 90% of its antioxidant activity after a 15-minute exposure at 85°C, thereby making it suitable for most confectionery manufacturing processes, including those based on gelatin.

Q3. Is HMC compatible with acidic vitamin C blends in beverages?

The compound remains stable in a pH range of 2.5–6.8, and no degradation is observed when combined with ascorbic acid during 12-month accelerated shelf-life testing.

Related Information

Common Preparation Methods

HMC synthesis is initiated by dissolving hesperidin extract in a methanol-water solution (70:30 v/v) heated to 60°C with continuous stirring. Methylation is achieved via the controlled addition of dimethyl sulphate under alkaline conditions (pH 9–10 maintained by 1 M NaOH), with the reaction proceeding for 2 hours at 80°C. Consequently, the mixture is immediately neutralised to pH 7.0 using food-grade citric acid upon completion of the reaction. Crystallisation follows by gradually cooling the solution to 5°C over 4 hours, yielding crude methyl chalcone crystals that are recovered by vacuum filtration. Purification involves recrystallisation from an ethanol-water mixture (85:15) and a 0.1% activated carbon treatment at 75°C for decolourisation purposes. Final micronisation is performed via jet milling under a nitrogen atmosphere to achieve the target particle size (D90<20 µm). This process delivers pharmaceutical-grade HMC with purity exceeding 98%, residual solvent content below 0.1%, and thermal stability up to 85°C.